Member Info for Aether

What impact will good deep dive SPRINTER 3, Active-2 P2, and Long Covid data have on the sp?
If the data is good, what are the chances that a Big Pharma will offer a TO?
Will it take a TO offer to raise the price above £1?

If the deep dive SPRINTR 3, Active-2 P2, Long Covid data is good will this raise the share price significantly?
Perhaps only a TO offer will do that. But will a Big Pharma be interested in SNG if the data is good?

Green bin it.

Don't feed it.

Green bin it.

Don't feed it.

What do you think are the prospects for SNG, MrCosts?

Can someone contact the original twitter poster to find out?

Whatever they informed Polygon over the weekend before the RNS was released, it was enough to cause them to buy up to 25%.

Where did he get this information from?

https://twitter.com/AIMdective/status/1508705554566426626?cxt=HHwWhMC5qavt_-8pAAAA

"US buyer continues to buy @Synairgenplc shares post market close. This has happened for several days. Estimation is they are very close to 3%."

Is this true?

Are you holding FTC7?

I am holding because the scale of the losses are so large it makes no difference.

The deep dive data, etc will be critical to determine whether there will be a TO by a larger pharmaceutical company.

A TO is our best option to extricate ourselves from this share in the short to medium term.

Yes. The deep dive, etc is critical.

Andy, Burs, W, and others seem disturbed.

It provides a more accurate assessment of the efficacy of the drug. For example, by removing patients who have taken steroids or other confounding factors.

Hargreaves Lansdown now reporting big sells.

I suspect Poly just want to extricate themselves from the share at this point.
Although, I am interested in what they were told over the weekend prior to the release of the RNS that my have convinced them to invest further.

A TO seems the most likely outcome if the deep dive data is good.

It isn't Synairgen running the numbers. Why is it taking so long?

This is taking longer than anticipated.

Hargreaves Lansdown showing very strong buys overall.

Perhaps that's the reason it is taking longer than expected.

At this stage, a TO by a large pharmaceutical company seems the best option to extricate from the share.